Skip to main content

and
  1. Article

    Open Access

    Successful implementation of online educational lectures of the German Society for Radiation Oncology (DEGRO)

    Modern digital teaching formats have become increasingly important in recent years, in part due to the COVID-19 pandemic. In January 2021, an online-based webinar series was established by the German Society f...

    Marcel Büttner, Philip Melton, Rainer Fietkau in Strahlentherapie und Onkologie (2024)

  2. Article

    Open Access

    Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors

    This review article is intended to provide a perspective overview of potential strategies to overcome radiation resistance of tumors through the combined use of immune checkpoint and DNA repair inhibitors.

    Sandra Classen, Cordula Petersen, Kerstin Borgmann in Strahlentherapie und Onkologie (2023)

  3. No Access

    Article

    DNA as the main target in radiotherapy—a historical overview from first isolation to anti-tumour immune response

    DNA damage is one of the foremost mechanisms of irradiation at the biological level. After the first isolation of DNA by Friedrich Miescher in the 19th century, the structure of DNA was described by Watson and...

    Benjamin Frey, Kerstin Borgmann, Tina Jost in Strahlentherapie und Onkologie (2023)

  4. No Access

    Living Reference Work Entry In depth

    Basic Radiobiology

    In recent years, clinical radiotherapy has undergone considerable further development. This was primarily due to technological progress in adapting the radiation fields, the increasing adaptation of cytostatic...

    Ann Christin Parplys, Kerstin Borgmann in Radiation Oncology

  5. Article

    Open Access

    Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy

    To examine the association of polymorphisms in ATM (codon 158), GSTP1 (codon 105), SOD2 (codon 16), TGFB1 (position −509), XPD (codon 751), and XRCC1 (codon 399) with the risk of severe erythema after breast cons...

    Annette Raabe, Katharina Derda, Sebastian Reuther, Silke Szymczak in Radiation Oncology (2012)

  6. No Access

    Article

    Zur Interaktion von Strahlentherapie und Tamoxifen beim Mammakarzinom

    Tamoxifen (TAM) ist in der adjuvanten Therapie des Mammakarzinoms ebenso etabliert wie die Strahlentherapie; der optimale Zeitpunkt für den Beginn der Therapie mit TAM – simultan zur oder sequentiell nach Stra...

    PD Dr. Ulrike Hoeller, Kerstin Borgmann, Petra Feyer* in Strahlentherapie und Onkologie (2007)